As reported by PharmaTimes, Astellas Pharma, the top 20 pharmaceutical company, has recently unveiled their new five year plan which it hopes will lead to a 30% rise in earnings by March 2015.
The Japanese pharmaceutical company has set a target of operating profit of 240 billion yen for the year to March 2015. This is up 186.40 yen from the last fiscal year.
The plan is said to be a bid to combat the effects of generic competition it its highest earning drugs:
- Prograf – an immunosuppressant
- Harnal – a treatment for benign prostatic hyperplasia
The pharmaceutical company has announced that it will now concentrate on becoming a ‘global category leader’ in the following three areas:
- Urology
- Transplantation
- Oncology
Astellas Pharma also plans to further strengthen their sales network in emerging networks, in particular China. The pharmaceutical company plans to increase the number of sales representatives they have in china to more than 600.
Looking for a job in the pharmaceutical industry? Click here to search our current pharmaceutical jobs.
